Abstract No : Abstract #890MO
Indication : Diffuse large B-cell lymphoma
Intervention : AUTO3
Company : Merck & Co.
Technology : CAR T cell therapy
As of April 27, 2020, 23 patients were treated with AUTO3 in the ongoing phase I study. The median age was 57 (28 - 83) and median number of prior therapies was 3 (2 - 10). 87% had refractory disease, 74% were DLBCL NOS, and 26% were tDLBCL. Dose escalation from 50 to 450 x 106 cells with pem regimen A and B have been completed without DLTs. G ≥ 3 treatment emergent AEs that occurred ≥ 25% were neutropenia (87%), thrombocytopenia (57%), and anemia (48%). Majority of Serious AE were hematological related and reversible. There were 0 cases of severe cytokine release syndrome (sCRS) or neurotoxicity (NT) of any grade at > 50 x 106 cells. Among the 16 patients treated at dose > 50 x 106, the ORR was 69% and CRR was 56%, and all CRs are ongoing at a median f/u 3 months (1-12 months). Among the 8 patients treated at a dose > 50 x 106 with D-1 pem, the ORR was 75% and CRR was 63%. Additional data from patients treated at the recommended phase II dose as well as patients treated in an out-patient setting and longer follow up, as well as relevant biomarkers will be presented.
AUTO3 at > 50 x 106 CAR T cells with pembrolizumab induces CRs without severe CRS or NT of any grade.